Let Activefol.io Invest in NKTR on Your Behalf.

Stock Detail Header
  • Active Investing
  • Personalized Strategy
  • Low Monthly Fees
Get Started
Stock Details
  • PRICE$17.67
  • PRICE CHANGE$0.13
  • % CHANGE0.75%
  • TWEETS2
  • CONSENSUSHOLD

Trends

Course of Action

HOLD

Sentiment (10 days)

  •  Strong Buy
  •  Buy
  •  Hold
  •  Sell
  •  Strong Sell

DAILY PRICE CHANGE VS SENTIMENT

  • BullishBullish
  • BearishBearish
  • SentimentSentiment
  • BarPrice

Why Does Investing Using an Automated Portfolio Management Works?

Activefol.io is an advanced system designed to automate securities investing. It is designed to screens, monitors and auto-trades elite stocks like "NEKTAR THERAPEUTICS (NKTR)" using its proprietary Artificial Intelligence. By using Activefol.io an investor augments its potential to accelerate his financial performance.

Recommended Usage

Converting your 401k to a Rollover IRA and systematically invest using ACTIVEFOL.IO from Stock Circles could be a great strategy to grow your retirement account while you still have a long horizon before retirement. Activefol.io proprietary portfolio manager invests in Large Cap US Stocks only to ensure that you are investing in highly liquid securities.

Based on historical performance, Activefol.io's model strategies historically outperformed the S&P since 2016. It holds the potential to grow retirement accounts quicker than passive investment vehicles using the same securities.Activefol.io provides systematic investment strategies that use price momentum to produce short-term trades to build wealth.

In the past 3 years, the system has outperformed the S&P. Activefol.io makes short-term trades. If these trades happen in a tax-deferred account, you do not get taxed until you start taking money out of the account. So if you start auto-trading today in your retirement account and invests for 10, 15, 20 years, imagine how much money a systematic strategy as the potential to create for you.

This investment system works great for tax-deferred accounts like Traditional and Roth IRAs. You can trade with a minimum of $25,000 in your account.

Activefol.io is very affordable. You will pay a low monthly management fee to use it. Using Activefol.io will usually pay for itself on the first successful trade of the month.

Systematic investing is powerful

Systematic investing with ACTIVEFOL.IO is easy. You do not need to know anything about stock investing. All you need to do is to set up your trading strategy and the automated portfolio manager will take care of the rest. Stock Circles offers a default strategy to help you get started. You can test the strategy in simulation mode free of charge today. Once comfortable with the outcome, suitable investors are ready to invest real money. You can then connect Activefol.io to your brokerage account and start to auto-trade.

Past performance does not guarantee future success. Activefol.io will do its best to take advantage of the market but if the market goes down for a long period of time then there is no money to be made and everyone holding these securities can be affected.

Activefol.io invests only elite stocks. By investing in the S&P 500®, Nasdaq 100™ and Dow 30™.

Activefol.io uses Artificial Intelligence concepts to screen, monitor and invest in securities. It monitors and invests on your behalf while you attend more important life events.

Take advantage of active investing strategies today by registering at stockcircles.com It's free to start in simulation mode.

Benefits

There are clear benefits associated with Activefol.io to help you reach your financial goals. Activefol.io simplifies stock investing down to a few steps. It invests for you, using your personalized strategy, while you attend more important life events.

Using Activefol.io is like having a professional portfolio manager working for you to help you reach your financial goals.

Activefol.io actively trades which is different from passive investing. The platform is on the lookout working to maximize your potential every minute of every business day of the year. It trades on the news taking advantage of price changes and trends by listening into trader's communications and by validating this information with market data.

Activefol.io is one of the first automated portfolio managers to take advantage of Government grade listening technology that produces emotional and rational indicators.

Try Activefol.io today!

You can test your strategy in simulation mode, risk free, Stock Circles today.

Get started now - and see where active automated trading can take you.

Disclaimer: Past performance may not be indicative of future results. Activefol.io like other investment methods rely on favorable market conditions to provide positive outcomes.

NEKTAR THERAPEUTICS (NKTR) News

Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy

Nektar Therapeutics (Nasdaq: NKTR) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NKTR-181, a new molecular entity (NME) and the first analgesic opioid molecule to exhibit a reduced incidence of specific CNS-mediated side effects, such as euphoria, through the targeted alteration of brain-entry kinetics.

"The submission of the NDA for NKTR-181 is an important milestone for Nektar, and we would like to thank our employees, investigators, clinical trial sites and most importantly the patients and families of those living with chronic pain for all of their help in the development of this medicine," said Steve Doberstein, Ph.D., Senior Vice President of Research and Development and Chief Development Officer at Nektar Therapeutics. "This innovative investigational medicine separates analgesic efficacy from the high levels of euphoria that too often lead to the abuse and addiction of traditional opioids."

The NDA is supported by an extensive clinical and nonclinical data package. The clinical data submitted in the NDA comprised 15 studies in 2,234 subjects and includes: a 600-patient efficacy study in patients with chronic low back pain who are new to opioid therapy; a 630-patient long-term 52-week safety study in patients with noncancer pain, who are new to opioid therapy, as well as those who are experienced with opioid therapy; pharmacokinetic/pharmacodynamic studies in over 450 subjects; and two human abuse potential studies evaluating both therapeutic and supratherapeutic doses of NKTR-181 versus an oxycodone control in recreational drug users.

Get Started today! - Risk Free

Investors who like NEKTAR THERAPEUTICS (NKTR) also like

Most Talked About Stocks on Stock Circles

Stock Bubbles